Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783712 | 0.89 | TGM2 (0.42) | TGM2ALDH1A1GRAMD1ATSHRALOX15 | |
| SCHEMBL6784352 | 0.85 | GPR119 (0.46) | TGM2ALDH1A1GPR119 | |
| SCHEMBL6785039 | 0.74 | GPR119 (0.46) | TGM2ALDH1A1GPR119 | |
| SCHEMBL15703241 | 0.72 | MAPT (0.61) | ALDH1A1TSHRALOX15GPR119HTT | |
| SCHEMBL15740834 | 0.71 | USP2 (0.42) | ALDH1A1GPR119MMP13ADAM17MAPT | |
| SCHEMBL15740512 | 0.70 | USP2 (0.44) | ALDH1A1GPR119MMP13ADAM17SMN1; SMN2 | |
| SCHEMBL4276127 | 0.70 | USP2 (0.44) | ALDH1A1TSHRALOX15GPR119HTT | |
| SCHEMBL29087334 | 0.70 | MEN1 (0.41) | ALDH1A1GRAMD1ATSHRALOX15GPR119 | |
| SCHEMBL3885184 | 0.69 | MAPT (0.62) | ALDH1A1GRAMD1ATSHRHTTMAPT | |
| SCHEMBL27391502 | 0.69 | GPR119 (0.52) | ALDH1A1GPR119HTTMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710060-B2 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-6642257-B2 | Fewer side-effects than do the conventional analgesics; 4-hydroxypiperidine derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020049229-A1 | Agents for treating neuropathic pain | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-1182193-A1 | REMEDIES FOR NEUROPATHIC PAIN | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049229-A1 | Agents for treating neuropathic pain | OPRM1, OPRK1, OPRL1 | TGM2 2085/4885ALDH1A1 310/4885GRAMD1A 4480/4885 |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | SCN5A, RYR2, SCN1B | TGM2 3984/4885ALDH1A1 416/4885GRAMD1A 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.